Paris-based AB Science has scored a rare late-stage clinical triumph in the Alzheimer’s disease field with a drug that puts brakes on inflammation in the brain.
Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s.
Although the company hasn’t released the exact numbers, it has reported that “significantly fewer” of the patients treated with masitinib progressed to severe dementia compared to those given a placebo. They also scored higher on cognition and memory tests. The test subjects took the candidate in addition to standard Alzheimer’s disease medications.
Masitinib is a drug that inhibits tyrosine kinase proteins, which are involved in promoting inflammation. The candidate was originally developed as a cancer drug and has also succeeded in phase III trials to treat amyotrophic lateral sclerosis (ALS). However, over the last several years, the drug has been plagued with clinical trial halts and rejection from the EMA for ALS and cancer, in part because the clinical data wasn’t seen as reliable enough.
AB Science’s approach embodies a new wave of medical thinking about Alzheimer’s disease and neurodegenerative disorders in general. For years, the focus of Alzheimer’s research had been on the buildup of misfolded proteins in the brain,
The post Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation appeared first on Labiotech.eu.
Published on Mon, 21 Dec 2020 14:16:32 +0000 and brought to you by power apps exchange rate